This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
AI-Generated Summary This article by infectious diseases pharmacist Aneeka Chavda outlines five key considerations for pharmacists in the treatment of Mycobacterium tuberculosis (TB), particularly drug-sensitive cases. The piece advocates for therapeutic drug monitoring (TDM) in specific high-risk groups to personalize treatment.
1,2 “There is an extraordinary unmet need in obesity treatment, which is the ability for patients to stop GLP-1 drugs without regaining weight. 1 “These early Revita data are better than I expected and suggest the potential to prevent the weight regain we see in practice.
Robert Barrie July 2, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Yeztugo, injected twice a year, offers more convenient dosing than daily pills. The US Food and Drug Administration (FDA) approved Yeztugo last month , bringing a more convenient PrEP option for adults and adolescents at risk of HIV exposure.
The presentation emphasized early intervention and personalized treatment plans in managing type 2 diabetes, shifting from "treating to failure" to "treating to target." It is not indicated for type 1 diabetes and carries a boxed warning for thyroid C-cell tumors, with unknown risk in humans.
Robert Barrie June 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Gilead said it is “committed to working with regulatory authorities to resolve the issues underlying the clinical hold” Credit: Melnikov Dmitriy via Shutterstock. Gilead is considered the leading big pharma in HIVtreatments.
Meloxicam injection (Xifyrm; Azurity Pharmaceuticals, Inc) received FDA approval for use in adults for the management of moderate-to-severe pain, either alone or in combination with non-steroidal anti-inflammatory drug (NSAID) analgesics.
SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy.
She emphasizes that treatment options are mostly supportive, making prevention through good hygiene and vaccination essential. Pharmacists play a crucial role in educating high-risk individuals about RSV risks and encouraging vaccination to reduce severe illness.
SHOW MORE Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis. Ongoing research explores tafamidis' long-term efficacy, potential in other heart failure forms, and combination therapies for enhanced outcomes.
Anti-TNFs remain the only FDA-approved class for pediatric IBD, prompting biosimilar use for cost and accessibility. Further research is needed on the clinical impact, treatment longevity, and cost implications of biosimilar use in pediatric IBD. SHOW MORE The study found biosimilar initiation rose to nearly 42% from 2016 to 2023.
I wonder if this will cause us to be more fragmented as a group in 2025 and if Bluesky will really have sticking power. Twice-Yearly Lenacapavir or Daily F/TAF for HIVPrevention in Cisgender Women | NEJM PURPOSE 1 RCT : No participants receiving twice-yearly lenacapavir acquired HIV infection. Mastodon sure did not.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content